1. 203 Population pharmacokinetics of MEDI4736, a fully human antiprogrammed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors. (September 2015) Authors: Song, X.; Pak, M.; Chavez, C.; Liang, M.; Lu, H.; Blake-Haskins, A.J.; Robbins, P.B.; Jin, X.; Gupta, A.; Roskos, L.; Narwal, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0167 Pharmacokinetics of Sifalimumab and Target Modulation of a Type I Interferon Gene Signature in Patients with Moderate to Severe Systemic Lupus Erythematosus. (9th June 2015) Authors: Morehouse, C.; Brohawn, P.; Higgs, B.; Zheng, B.; Yao, Y.; Roskos, L.; Robbie, G. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 946 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0576 Evaluation of surfactant protein-D and KL-6 as potential pulmonary safety biomarkers during mavrilimumab treatment. (23rd January 2014) Authors: Spitz, S.; Wilkins, D.; Esfandiari, E.; Godwood, A.; Roskos, L.; Ryan, P.; Magrini, F. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0182 Pharmacokinetics and immunogenicity of mavrilimumab administered subcutaneously in subjects with rheumatoid arthritis. (23rd January 2014) Authors: Wu, C.-Y.; Chen, X.; Lu, H.; Esfandiari, E.; Magrini, F.; Godwood, A.; Ryan, P.; Kane, C.; Roskos, L.; Wang, B. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0260 Biomarkers Associated with Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate with Changes in Clinical Response in Subjects Treated with Mavrilimumab at Doses above 10 Mg. (10th June 2014) Authors: White, W.; Ryan, P.C.; Guo, X.; Sinibaldi, D.; Ranganna, G.; Godwood, A.; Saurigny, D.; Close, D.; Eck, S.; Wilkins, D.; Roskos, L.; Sleeman, M.; Li, W.; Cavet, G.; Defranoux, N. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗